Rimegepant (Vydura®). HTA ID: 22051

Assessment Status NCPE Assessment Process Complete
HTA ID 22051
Drug Rimegepant
Brand Vydura®
Indication For the acute treatment of migraine with or without aura in adults; and for the preventive treatment of episodic migraine in adults who have at least four migraine attacks per month.
Assessment Process
Rapid review commissioned 13/07/2022
Rapid review completed 12/09/2022
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of rimegepant (Vydura®) compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 28/09/2022
Pre-submission consultation with Applicant 10/11/2022
Full submission received from Applicant 07/02/2023
Preliminary review sent to Applicant 27/03/2023
NCPE assessment re-commenced 18/04/2023
Factual accuracy sent to Applicant 03/05/2023
NCPE assessment re-commenced 10/05/2023
NCPE assessment completed 18/05/2023
NCPE assessment outcome The NCPE recommends that rimegepant (Vydura®) be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments and that a managed access programme is introduced*.

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.